Skip to content

CNO Financial Group CNO Fixed interest annuities — Capitalizations

Other product segments

Fixed indexed annuities
$13M-9.1%

Other financials

Income statement

See full
Revenue$1.0B+2.5%
Net income$37.7M+75.3%
EPS (diluted)$0.39+85.7%

Balance sheet

See full
Cash & equivalents$1.2B+12.6%
Total debt$1.4B-41.0%
Total equity$2.5B-2.2%
Total assets$39.0B+4.1%

Cash flow

See full
Operating cash flow$148.8M+8.9%

Valuation

See full
Market cap$4.93B-7.9%

Profitability

See full
Net margin5.4%-2.2pp

Returns & leverage

See full
Return on equity9.7%-3.7pp
Debt / equity0.5×-0.4×

Where this comes from

Reported directly by CNO Financial Group in its filing.

Tagged under the XBRL concept us-gaap:DeferredSalesInducementsAdditions.

The official record: CNO Financial Group’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CNO Financial Group's fixed interest annuities — capitalizations.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CNO Financial Group's fixed interest annuities — capitalizations?
CNO Financial Group (CNO) reported fixed interest annuities — capitalizations of $500K in Q1 2026.
How has CNO Financial Group's fixed interest annuities — capitalizations changed year-over-year?
CNO Financial Group's fixed interest annuities — capitalizations decreased by 16.7% year-over-year, from $600K to $500K.
What is the long-term trend for CNO Financial Group's fixed interest annuities — capitalizations?
Over 4 years (2021 to 2025), CNO Financial Group's fixed interest annuities — capitalizations has grown at a 86.1% compound annual growth rate (CAGR), from $200K to $2.4M.
What does fixed interest annuities — capitalizations mean?
This metric tracks the costs incurred during the acquisition or issuance of annuity contracts that are deferred and capitalized as assets rather than expensed immediately. It provides insight into the company's investment in business growth and the accounting treatment of acquisition-related expenditures.